IDEXX Laboratories, Inc. $IDXX Position Reduced by Brasada Capital Management LP

Brasada Capital Management LP lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,859 shares of the company’s stock after selling 1,426 shares during the period. IDEXX Laboratories comprises approximately 3.3% of Brasada Capital Management LP’s investment portfolio, making the stock its 5th largest holding. Brasada Capital Management LP’s holdings in IDEXX Laboratories were worth $19,335,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. EverSource Wealth Advisors LLC lifted its position in shares of IDEXX Laboratories by 2.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock valued at $397,000 after buying an additional 15 shares in the last quarter. Harbour Investments Inc. lifted its position in shares of IDEXX Laboratories by 13.3% during the 4th quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock valued at $92,000 after buying an additional 16 shares in the last quarter. CWA Asset Management Group LLC lifted its position in shares of IDEXX Laboratories by 3.5% during the 4th quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock valued at $344,000 after buying an additional 17 shares in the last quarter. Stratos Wealth Partners LTD. lifted its position in shares of IDEXX Laboratories by 1.7% during the 3rd quarter. Stratos Wealth Partners LTD. now owns 1,069 shares of the company’s stock valued at $683,000 after buying an additional 18 shares in the last quarter. Finally, Cary Street Partners Investment Advisory LLC lifted its position in shares of IDEXX Laboratories by 11.5% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 174 shares of the company’s stock valued at $111,000 after buying an additional 18 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 0.5%

NASDAQ IDXX opened at $560.88 on Friday. IDEXX Laboratories, Inc. has a 52 week low of $506.91 and a 52 week high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The business’s fifty day simple moving average is $563.06 and its 200-day simple moving average is $627.69. The firm has a market cap of $44.24 billion, a PE ratio of 41.30, a P/E/G ratio of 3.07 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the previous year, the firm earned $2.91 EPS. The company’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of research reports. Citigroup initiated coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective on the stock. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday. Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Finally, UBS Group decreased their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.